149507-26-6 Usage
Description
3-Fluoro-4-methoxybenzeneboronic acid is an organic compound with the molecular formula C7H8BFO3. It is a white solid that contains varying amounts of anhydride. 3-Fluoro-4-methoxybenzeneboronic acid is known for its reactivity and is commonly used as a reagent in various chemical reactions, particularly in the field of organic synthesis.
Uses
1. Used in Pharmaceutical Industry:
3-Fluoro-4-methoxybenzeneboronic acid is used as a reactant for the preparation of hydroxyphenylnaphthols, which serve as 17β-hydroxysteroid dehydrogenase Type 2 inhibitors. These inhibitors play a crucial role in the development of drugs targeting hormonal imbalances and related conditions.
2. Used in Organic Synthesis:
3-Fluoro-4-methoxybenzeneboronic acid is used as a reagent in regioselective Suzuki coupling reactions. This type of reaction is essential in the formation of carbon-carbon bonds, which are vital in the synthesis of complex organic molecules, including pharmaceuticals and agrochemicals.
3. Used in Catalyst Industry:
3-Fluoro-4-methoxybenzeneboronic acid is also used in ruthenium-catalyzed arylation reactions, which are significant in the synthesis of various organic compounds, including those with potential applications in the pharmaceutical and chemical industries.
4. Used in Anticancer Research:
3-Fluoro-4-methoxybenzeneboronic acid is utilized in the synthesis of amino-trimethoxyphenyl-aryl thiazoles, which have been identified as microtubule inhibitors and potential antitumor agents. These compounds are being investigated for their potential use in the development of novel anticancer drugs.
5. Used in Cyanation Reactions:
3-Fluoro-4-methoxybenzeneboronic acid is employed in rhodium-catalyzed cyanation reactions, which are essential in the synthesis of various organic compounds, including those with potential applications in the pharmaceutical and chemical industries.
6. Used in Petasis Reaction:
3-Fluoro-4-methoxybenzeneboronic acid is also used in the Petasis reaction, a type of chemical reaction that involves the formation of boronic esters from aldehydes and boronic acids. This reaction is crucial in the synthesis of various organic compounds, including those with potential applications in the pharmaceutical and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 149507-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,5,0 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 149507-26:
(8*1)+(7*4)+(6*9)+(5*5)+(4*0)+(3*7)+(2*2)+(1*6)=146
146 % 10 = 6
So 149507-26-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H10F3NO2/c1-2-19-12(18)10(8-17)7-9-3-5-11(6-4-9)13(14,15)16/h3-7H,2H2,1H3/b10-7+
149507-26-6Relevant articles and documents
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles
Sang, Yali,Han, Sheng,Pannecouque, Christophe,De Clercq, Erik,Zhuang, Chunlin,Chen, Fener
, p. 11430 - 11436 (2019)
A series of nondimethylphenyl-diarylpyrimidines with much lower cytotoxicities than their dimethyl analogues were developed. Compound B13 with a difluorobiphenyl moiety showed the highest antiviral activity against WT, mutant strains, and RT. The hydrochloride form of B13 exhibited an improved water solubility of 5.6 μg/mL compared with ETR (?1 μg/mL), better stability in human and rat liver microsomes, and a great oral bioavailability of 44%, making it promising as a drug candidate. In addition, no apparent toxicity was observed in the acute toxicity assay (2 g/kg) and HE staining.
HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS
-
Page 17; 28, (2008/06/13)
This invention provides estrogen receptor modulators having the structure formula (I): wherein R1 to R6 and R8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
Substituted phenyl naphthalenes as estrogenic agents
-
, (2008/06/13)
This invention provides estrogen receptor modulators of formula I, having the structure 1wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.
